Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBT Margin (2021 - 2025)

Historic EBT Margin for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to 247.29%.

  • InMed Pharmaceuticals' EBT Margin fell 156600.0% to 247.29% in Q4 2025 from the same period last year, while for Dec 2025 it was 170.07%, marking a year-over-year decrease of 64500.0%. This contributed to the annual value of 165.14% for FY2025, which is 16500.0% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its EBT Margin stood at 247.29% for Q4 2025, which was down 156600.0% from 154.17% recorded in Q3 2025.
  • InMed Pharmaceuticals' 5-year EBT Margin high stood at 14.56% for Q2 2023, and its period low was 1615.6% during Q4 2021.
  • For the 5-year period, InMed Pharmaceuticals' EBT Margin averaged around 457.79%, with its median value being 193.09% (2023).
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 15143100bps in 2023, then plummeted by -1359000bps in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' EBT Margin stood at 1615.6% in 2021, then surged by 72bps to 446.61% in 2022, then soared by 73bps to 119.19% in 2023, then crashed by -94bps to 231.63% in 2024, then dropped by -7bps to 247.29% in 2025.
  • Its EBT Margin stands at 247.29% for Q4 2025, versus 154.17% for Q3 2025 and 137.07% for Q2 2025.